RETRACTION: Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study (Retraction of Vol 5, Pg 785, 2017)

被引：0
|
作者：
Waterer, Grant [1 ]
机构：
[1] Lancet Resp Med, London EC2Y 5AS, England
来源：
LANCET RESPIRATORY MEDICINE | 2024年 / 12卷 / 04期
关键词：
D O I：
10.1016/S2213-2600(24)00029-8
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：262 / 263
页数：2
相关论文
共 50 条
  • [21] Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial (vol 396, pg 909, 2020)
    Horne, A. W.
    Vincent, K.
    Hewitt, C. A.
    LANCET, 2020, 396 (10259): : 1334 - 1334
  • [22] NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (vol 391, pg 1174, 2018)
    Harrison, S. A.
    Rinella, M. E.
    Abdelmalek, M. F.
    LANCET, 2018, 391 (10126): : E16 - E16
  • [23] Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 402, pg 775, 2023)
    Pozo-Rosich, P.
    Ailani, J.
    Ashina, M.
    LANCET, 2023, 402 (10410): : 1328 - 1328
  • [24] Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 402, pg 775, 2023)
    Pozo-Rosich, P.
    Ailani, J.
    Ashina, M.
    LANCET, 2023, 402 (10404): : 774 - 774
  • [25] Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
    Bigal, Marcelo E.
    Edvinsson, Lars
    Rapoport, Alan M.
    Lipton, Richard B.
    Spierings, Egilius L. H.
    Diener, Hans-Christoph
    Burstein, Rami
    Loupe, Pippa S.
    Ma, Yuju
    Yang, Ronghua
    Silberstein, Stephen D.
    LANCET NEUROLOGY, 2015, 14 (11): : 1091 - 1100
  • [26] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (vol 21, pg 125, 2022)
    Mignot, E.
    Mayleben, D.
    Fietzeet, I
    LANCET NEUROLOGY, 2022, 21 (03):
  • [27] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (vol 21, pg 125, 2022)
    Mignot, E.
    Mayleben, D.
    Fietze, I
    LANCET NEUROLOGY, 2022, 21 (06): : E6 - E6
  • [28] Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
    Baudin, Eric
    Goichot, Bernard
    Berruti, Alfredo
    Hadoux, Julien
    Moalla, Salma
    Laboureau, Sandrine
    Noelting, Svenja
    de la Fouchardiere, Christelle
    Kienitz, Tina
    Deutschbein, Timo
    Zovato, Stefania
    Amar, Laurence
    Haissaguerre, Magalie
    Timmers, Henri
    Niccoli, Patricia
    Faggiano, Antongiulio
    Angokai, Moussa
    Lamartina, Livia
    Luca, Florina
    Cosentini, Deborah
    Hahner, Stefanie
    Beuschlein, Felix
    Attard, Marie
    Texier, Matthieu
    Fassnacht, Martin
    LANCET, 2024, 403 (10431): : 1061 - 1070
  • [29] RETRACTION: Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects (Retraction of Vol 5, Pg 21, 2012)
    Vinson, J. A.
    Burnham, B. R.
    Nagendran, M., V
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2014, 7 : 467 - 467
  • [30] RETRACTION: Treatment of postoperative emetic symptoms with granisetron in women undergoing abdominal hysterectomy: A randomized, double-blind, placebo-controlled, dose-ranging study (Retraction of Vol 65, Pg 321, 2004)
    Fujii, Yoshitaka
    Tanaka, Hiroyoshi
    Somekawa, Yoshiaki
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2018, 88 : 53 - 53
12345